Eledon PharmaceuticalsELDN
ELDN
About: Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Employees: 31
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
11% more funds holding
Funds holding: 75 [Q4 2024] → 83 (+8) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.22% less ownership
Funds ownership: 64.43% [Q4 2024] → 64.21% (-0.22%) [Q1 2025]
18% less capital invested
Capital invested by funds: $159M [Q4 2024] → $130M (-$28.3M) [Q1 2025]
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
87% less call options, than puts
Call options by funds: $36K | Put options by funds: $282K
Research analyst outlook
We haven’t received any recent analyst ratings for ELDN.
Financial journalist opinion
Positive
Zacks Investment Research
3 weeks ago
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock
Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
GlobeNewsWire
1 month ago
Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Cash, cash equivalents and short-term investments of $124.9 million as of March 31, 2025 IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its first quarter 2025 operating and financial results and reviewed recent business highlights.
Neutral
Seeking Alpha
1 month ago
Undercovered Dozen: Gevo, Eledon, Dorian, Iridium +
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering potential investment ideas and sparking community discussion. Aeluma, Inc. is a speculative microcap with game-changing semiconductor technology, a credible team, and significant grants, making it a strong buy. Big Yellow Group, despite macro pressures, shows steady revenue growth and strong cash generation, presenting a buy opportunity for long-term investors.
Positive
Seeking Alpha
1 month ago
Eledon: A Company With Good Early Data In Kidney Transplant Rejection And A Full Balance Sheet
Eledon Pharmaceuticals' lead candidate, tegoprubart, shows promise in improving kidney function post-transplant, potentially becoming the new standard-of-care over tacrolimus. With a significant total addressable market, tegoprubart could address over 25,000 new kidney transplant patients annually, translating to a $6B market opportunity. The upcoming Phase 2 study data in Q4 2025 is a critical milestone, with potential for transformative value and a possible $6B buyout valuation.
Neutral
GlobeNewsWire
2 months ago
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025 Proceeds from oversubscribed $85 million underwritten offering extend cash runway to end of 2026 IRVINE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its fourth quarter and full year 2024 operating and financial results and reviewed recent business highlights.
Neutral
GlobeNewsWire
3 months ago
Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D.
Neutral
GlobeNewsWire
4 months ago
Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human
Neutral
GlobeNewsWire
4 months ago
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Positive
Seeking Alpha
4 months ago
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $264mn, a cash balance of $78mn, and a cash runway of 7-8 quarters, but remains a high-risk investment.
Neutral
GlobeNewsWire
5 months ago
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Completed two financings totaling $135 million in combined gross proceeds, with funds expected to support operations through end of 2026 IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced a summary of 2024 accomplishments and provided guidance for anticipated 2025 business milestones.
Charts implemented using Lightweight Charts™